Versant Spin-Off Delivers 5% FCF Yield, 40% Below Peers
VSNT•Versant’s May 2026 spin-off of its drug development unit delivered a standalone free cash flow yield of 5%, compared with the 8% peer average. This 40% valuation gap suggests a potential 25% upside if cash flow multiples re-rate over the next year.
1. Spin-Off Execution
In May 2026, Versant completed the spin-off of its drug development unit, distributing standalone shares to existing investors and establishing independent financial reporting.
2. Valuation Implications
The newly independent entity posted a 5% free cash flow yield on an annualized basis, 40% below the 8% average among comparable peers, suggesting potential undervaluation and rerating catalysts.
